Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1/2, Dose-escalation and Expansion Study of SBT6050 Combined With Other HER2-directed Therapies in Subjects With Pretreated Unresectable Locally Advanced and/or Metastatic HER2-expressing or HER2-amplified Cancers

NCT05091528 is registered in ClinicalTrials.gov with Silverback Therapeutics as lead sponsor.

NCT NCT05091528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05091528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1/2, Dose-escalation and Expansion Study of SBT6050 Combined With Other HER2-directed Therapies in Subjects With Pretreated Unresectable Locally Advanced and/or Metastatic HER2-expressing or HER2-amplified Cancers
Lead sponsor
Silverback Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
February 8, 2022
Completion date
July 7, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-expressing non-small cell lung cancer, her2-positive breast cancer, her2-positive colorectal cancer, her2-positive gastric cancer